Sound Biologics

Sound Biologics is a privately held biotechnology company specializing in the discovery and development of novel biotherapeutics for oncology. The company's MabPair technology is a powerful new platform capable of producing two distinct monoclonal antibodies from a single cell line. Compared to bispecific antibody products or conventional antibody combinations, products derived from the MabPair platform offer compelling advantages, including full flexibility in selecting different Fc backbones for antibody effector functions, simplified regulatory and clinical development pathways, and single-entity pricing capabilities. Sound Biologics is actively seeking discovery and clinical collaborations while continuing to build a robust R&D pipeline.